CDK4 and female reproductive organ cancer: These results suggest that the multi-node inhibition of the PAM pathway by gedatolisib, in combination with anti-estrogens and/or CDK4/6 inhibitors, could be an effective therapeutic strategy for the treatment of gynecologic cancers.